A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

The FDA and European Medicines Agency (EMA) have granted authorization for a confirmatory phase 3 trial that will evaluate masitinib in metastatic castrate-resistant prostate cancer (mCRPC), AB ...

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

On June 18, 2025, the FDA granted clearance to Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for the treatment of patients with urinary urge incontinence. 1 In this video, Andrea ...

Treatment of non-metastatic hormone-sensitive prostate cancer (nmHSPC) with enzalutamide (Xtandi) in combination with leuprolide acetate was associated with significantly improved overall survival (OS ...

The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for nogapendekin alfa inbakicept-pmln (NAI, Anktiva) in combination with BCG for the ...

Patient enrollment has been completed for the phase 3 UTOPIA trial (NCT06331299) evaluating UGN-103 (mitomycin) for intravesical solution for the treatment of recurrent low-grade intermediate risk non ...

"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E.

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.